159 related articles for article (PubMed ID: 33970392)
1. Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography.
Zhu Q; Ademuyiwa FO; Young C; Appleton C; Covington MF; Ma C; Sanati S; Hagemann IS; Mostafa A; Uddin KMS; Grigsby I; Frith AE; Hernandez-Aya LF; Poplack SS
Breast Cancer Res Treat; 2021 Aug; 188(3):615-630. PubMed ID: 33970392
[TBL] [Abstract][Full Text] [Related]
2. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Zhu Q; DeFusco PA; Ricci A; Cronin EB; Hegde PU; Kane M; Tavakoli B; Xu Y; Hart J; Tannenbaum SH
Radiology; 2013 Feb; 266(2):433-42. PubMed ID: 23264349
[TBL] [Abstract][Full Text] [Related]
4. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
5. Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
Deng B; Muldoon A; Cormier J; Mercaldo ND; Niehoff E; Moffett N; Saksena MA; Isakoff SJ; Carp SA
J Biomed Opt; 2024 Jun; 29(6):066001. PubMed ID: 38737790
[TBL] [Abstract][Full Text] [Related]
6. Predicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatment.
Jiang S; Pogue BW; Kaufman PA; Gui J; Jermyn M; Frazee TE; Poplack SP; DiFlorio-Alexander R; Wells WA; Paulsen KD
Clin Cancer Res; 2014 Dec; 20(23):6006-15. PubMed ID: 25294916
[TBL] [Abstract][Full Text] [Related]
7. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria.
Zhu Q; Wang L; Tannenbaum S; Ricci A; DeFusco P; Hegde P
Breast Cancer Res; 2014 Oct; 16(5):456. PubMed ID: 25349073
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
10. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
11. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
12. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
13. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
14. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
15. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
[TBL] [Abstract][Full Text] [Related]
16. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
Braman N; Prasanna P; Whitney J; Singh S; Beig N; Etesami M; Bates DDB; Gallagher K; Bloch BN; Vulchi M; Turk P; Bera K; Abraham J; Sikov WM; Somlo G; Harris LN; Gilmore H; Plecha D; Varadan V; Madabhushi A
JAMA Netw Open; 2019 Apr; 2(4):e192561. PubMed ID: 31002322
[TBL] [Abstract][Full Text] [Related]
17. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
19. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
Lim EA; Gunther JE; Kim HK; Flexman M; Hibshoosh H; Crew K; Taback B; Campbell J; Kalinsky K; Hielscher A; Hershman DL
Breast Cancer Res Treat; 2017 Apr; 162(3):533-540. PubMed ID: 28190249
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
